Evidence map›Paper›PMID 31375279›Full record

Trial reportEuropean urology2019

Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.

Greetta Hackman, Kimmo Taari, Teuvo L Tammela, Mika Matikainen, Mauri Kouri, Timo Joensuu, Tiina Luukkaala, Arto Salonen, Taina Isotalo, Anssi Pétas and 12 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05232578 (Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness), which is not on this map. Cited by 51 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05232578 phase3not yet recruitingnot on this mapstarted 2022, after this paper: background citation

Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness

TypeinterventionalSponsorGeneral University Hospital, PragueRan2022 to 2032Enrolled380ConditionsProstate CancerArmsEarly salvage radiotherapy (eSRT), Delayed Salvage radiotherapy (dSRT)
3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047).Annals of oncology : official journal of the European Society for Medical Oncology · 2024
    Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Real world comparison of adjuvant vs. salvage radiation therapy on cancer-control outcomes after radical prostatectomy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. How to tailor the radiotherapy after radical prostatectomy in the modern era of molecular imaging, genomic testing, and technology development?Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Greetta HackmanFaculty of Medicine, University of Helsinki, Helsinki, Finland.
Kimmo TaariDepartment of Urology, Helsinki University Hospital, Helsinki, Finland.
Teuvo L TammelaDepartment of Surgery, Tampere University Hospital, Faculty of Medicine and Life Sciences, Tampere University, Tampere, Finland.
Mika MatikainenDepartment of Urology, Helsinki University Hospital, Helsinki, Finland.
Mauri KouriComprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
Timo JoensuuComprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland; Docrates Cancer Center, Helsinki, Finland.
Tiina LuukkaalaResearch, Development and Innovation Center, Tampere University Hospital and Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland.
Arto SalonenDepartment of Urology, Kuopio University Hospital, Kuopio, Finland.
Taina IsotaloDepartment of Urology, Päijät-Häme Central Hospital, Lahti, Finland.
Anssi PétasDepartment of Urology, Helsinki University Hospital, Helsinki, Finland.
Niilo HendolinDepartment of Surgery, Mikkeli Central Hospital, Mikkeli, Finland.
Peter J BoströmDepartment of Urology, Turku University Hospital, Turku, Finland.
Sirpa AaltomaaDepartment of Urology, Kuopio University Hospital, Kuopio, Finland.
Kari LehtorantaDepartment of Urology, Päijät-Häme Central Hospital, Lahti, Finland.
Pekka HellströmDepartment of Urology, Oulu University Hospital, Oulu, Finland.
Jarno RiikonenDepartment of Surgery, Tampere University Hospital, Faculty of Medicine and Life Sciences, Tampere University, Tampere, Finland.
Merja KorpelaDepartment of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.
Heikki MinnDepartment of Oncology, Turku University Hospital, Turku, Finland.
Pirkko-Liisa Kellokumpu-LehtinenDepartment of Oncology, Tampere University Hospital, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
Eero PukkalaFinnish Cancer Registry-Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland; Faculty of Social Sciences, University of Tampere, Tampere, Finland.
Akseli HemminkiComprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland; Docrates Cancer Center, Helsinki, Finland; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland. Electronic address: akseli.hemminki@helsinki.fi.
FinnProstate Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt remains unclear whether patients with positive surgical margins or extracapsular extension benefit from adjuvant radiotherapy following radical prostatectomy.

objectiveTo compare the effectiveness and tolerability of adjuvant radiotherapy following radical prostatectomy. DESIGN, SETTING, AND

participantsThis was a randomised, open-label, parallel-group trial. A total of 250 patients were enrolled between April 2004 and October 2012 in eight Finnish hospitals, with pT2 with positive margins or pT3a, pN0, M0 cancer without seminal vesicle invasion.

interventionA total of 126 patients received adjuvant radiotherapy at 66.6Gy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was biochemical recurrence-free survival, which we analysed using the Kaplan-Meier method and Cox proportional hazard regression. Overall survival, cancer-specific survival, local recurrence, and adverse events were secondary endpoints. RESULTS AND LIMITATIONS: The median follow-up time for patients who were alive when the follow-up ended was 9.3yr in the adjuvant group and 8.6yr in the observation group. The 10-yr survival for biochemical recurrence was 82% in the adjuvant group and 61% in the observation group (hazard ratio [HR] 0.26 [95% confidence interval {CI} 0.14-0.48], p<0.001), and for overall survival 92% and 87%, respectively (HR 0.69 [95% CI 0.29-1.60], p=0.4). Two and four metastatic cancers occurred, respectively. Out of the 43 patients with biochemical recurrence in the observation group, 37 patients received salvage radiotherapy. In the adjuvant group, 56% experienced grade 3 adverse events, versus 40% in the observation group (p=0.016). Only one grade 4 adverse event occurred (adjuvant group). A limitation of this study was the number of patients.

conclusionsAdjuvant radiotherapy following radical prostatectomy is generally well tolerated and prolongs biochemical recurrence-free survival compared with radical prostatectomy alone in patients with positive margins or extracapsular extension. PATIENT SUMMARY: Radiotherapy given immediately after prostate cancer surgery prolongs prostate-specific antigen progression-free survival, but causes more adverse events, when compared with surgery alone.

Indexed as

ProstateProstatectomyProstatic NeoplasmsRadiotherapy, AdjuvantAgedFollow-Up StudiesHumansKaplan-Meier EstimateMaleMargins of ExcisionMiddle AgedNeoplasm StagingOutcome Assessment, Health CareProportional Hazards ModelsProstate-Specific AntigenSurvival AnalysisProstate-Specific AntigenAdjuvant radiotherapyExtracapsular extensionPositive marginsProstate cancerRadical prostatectomy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.